Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...
Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.
DelveInsight's Hemophilia A Market Insights report includes a comprehensive understanding of current treatment practices, hemophilia A emerging drugs, market share of individual therapies, and current ...
A groundbreaking gene-editing method from UT Austin is changing the game for treating complex genetic diseases like cystic ...
Those successes, along with recent approvals for new treatments and expanding sales in developing countries, have ...
Today, we're seeing more women with hemophilia diagnosed earlier, but there's still work to do, says columnist.
In an era with less political and cultural division — and less tech-driven diversion — the stunning advances in medicine seen ...
Piper Sandler 37th Annual Healthcare Conference December 2, 2025 8:30 AM ESTCompany ParticipantsJacqueline Shea - ...
Columnist Allyx Formalejo says that she and her husband, Jared, are managing hemophilia in a less impulsive and more ...
The name “340B” comes from the section of the U.S. Public Health Service Act of 1992 that requires pharmaceutical ...
Researchers created a highly efficient gene-editing method that fixes multiple DNA mutations in a single step. The breakthrough could revolutionize genetic medicine by making treatments for complex ...
History Snob on MSN
You think you have problems? These royal families were cursed
Heavy is the head that wears the crown—especially when there's a curse hanging over it! While royal life may seem like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback